Financial Instruments - Long-Term Debt, Issuance (Details) - USD ($)		1 Months Ended
		May 31, 2023	Jul. 02, 2023
Debt Instrument [Line Items]
Effective interest rate		4.93%
Unsecured Debt [Member]
Debt Instrument [Line Items]
Face amount of debt issued		$ 31,000,000,000	$ 31,000,000,000	[1],[2],[3]
Redemption price percentage		101.00%
Unsecured Debt [Member] | Senior Unsecured Notes, 4.650%, Due May 2025 [Member]
Debt Instrument [Line Items]
Stated interest rate			4.65%
Face amount of debt issued	[1],[2],[4]		$ 3,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 4.450%, Due May 2026 [Member]
Debt Instrument [Line Items]
Stated interest rate			4.45%
Face amount of debt issued	[1],[2],[4]		$ 3,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 4.450%, Due May 2028 [Member]
Debt Instrument [Line Items]
Stated interest rate			4.45%
Face amount of debt issued	[1],[2],[4]		$ 4,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 4.650%, Due May 2030 [Member]
Debt Instrument [Line Items]
Stated interest rate			4.65%
Face amount of debt issued	[1],[2],[4]		$ 3,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 4.750%, Due May 2033 [Member]
Debt Instrument [Line Items]
Stated interest rate			4.75%
Face amount of debt issued	[1],[2]		$ 5,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 5.110%, Due May 2043 [Member]
Debt Instrument [Line Items]
Stated interest rate			5.11%
Face amount of debt issued	[1],[2],[4]		$ 3,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 5.300%, Due May 2053 [Member]
Debt Instrument [Line Items]
Stated interest rate			5.30%
Face amount of debt issued	[1],[2]		$ 6,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, 5.340%, Due May 2063 [Member]
Debt Instrument [Line Items]
Stated interest rate			5.34%
Face amount of debt issued	[1],[2],[4]		$ 4,000,000,000

[1] The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the proposed acquisition of Seagen and has no assets or operations and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.

[2] The notes may be redeemed by us at any time, in whole, or in part, at a make-whole redemption price plus accrued and unpaid interest.

[3] The weighted average effective interest rate for the notes at issuance was 4.93%.

[4] The notes are subject to a special mandatory redemption (at a price equal to 101% of the aggregate principal amount of such series of notes, plus any accrued and unpaid interest) under certain circumstances if the proposed acquisition of Seagen is terminated or does not close by an agreed upon date.